慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2019.05.015

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (5): 672-675.doi: 10.3969/j.issn.1672-5069.2019.05.015

慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*

朱玉成, 闫家微, 孙景坤, 张秋月

221000 江苏省徐州市传染病医院重症医学科（朱玉成,孙景坤）; 检验科（闫家微）; 徐州医科大学附属医院消化科（张秋月）

收稿日期:2018-08-20 出版日期:2019-09-10 发布日期:2019-09-16
通讯作者: 闫家微,E-mail:152341019@qq.com
作者简介:朱玉成,男,43岁,大学本科,副主任医师。E-mail: qhxsan@163.com
基金资助:
江苏省徐州市预防医学科研课题（编号：xzzd1265）

Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure

Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al

Intensive Care Unit,Infectious Disease Hospital,Xuzhou 221000,Jiangsu Province,China

Received:2018-08-20 Online:2019-09-10 Published:2019-09-16

摘要/Abstract

摘要： 目的探讨乙型肝炎相关的慢加急性肝衰竭（ACLF）患者血清二胺氧化酶（DAO）水平及其评估患者预后的价值。方法 2014年8月~2017年4月我院收治的104例ACLF患者,在治疗60 d内,生存64例,死亡40例。采用酶联免疫吸附法检测血清DAO水平,采用二元Logistic回归分析影响患者预后的因素。结果生存患者血清DAO水平为（15.1±4.8） ng/mL,显著低于死亡患者[（68.4±25.4） ng/mL,P<0.05];单因素分析显示年龄、TBIL、AST、ALT、INR、ALB、Cr、MEID评分、WBC、自发性细菌腹膜炎、肝性脑病、腹水和肝硬化与患者预后结局相关,多因素回归分析显示,MELD评分、年龄和血清DAO水平为影响患者预后的独立危险因素;DAO≥48.7 ng/mL与DAO<48.7 ng/mL患者生存率分别为50.0%和77.3%,差异有统计学意义（P<0.05）,MELD≥26.1分与MELD<26.1分患者生存率分别为45.5%和79.6%,差异有统计学意义（P<0.05）,年龄≥40岁与年龄<40岁的患者生存率分别为50.8%和79.5%,差异有统计学意义（P<0.05）。结论血清DAO水平也可以判断ACLF患者预后,为判断肝衰竭患者预后增加了一个可应用的指标,其作用还有待于进一步研究。

关键词: 慢加急性肝衰竭, 乙型肝炎, 二胺氧化酶, 预后

Abstract: Objective To investigate the changes of implication of serum diamine oxidase（DAO） level in patients with hepatitis B-induced acute-on-chronic liver failure（ACLF）. Methods A total of 104 patients with ACLF were admitted to our hospital between August 2014 and April 2017,and 64 patients survived and 40 died in 60 day observation. Serum DAO levels were detected by ELISA,and the factors affecting the prognosis of patients were analyzed by Logistic regression analysis. Results Serum DAO level in the survival group was （15.1±4.8） ng/mL,significantly lower than（68.4±25.4） ng/mL （P<0.05） in the fatal group;univariate analysis showed that serum TBIL,AST,ALT,INR,ALB,Cr,and MEID score,WBC,spontaneous bacterial peritonitis,hepatic encephalopathy,ascites,as well as cirrhosis were associated with the bad prognosis,and multivariate regression analysis demonstrated that high MELD scores,high DAO levels and patients’ age were the independent risk factors for death of patient with ACLF;the survival rates in patients with serum DAO≥48.7 ng/mL and with serum DAO<48.7 ng/mL were 50.0% and 77.3% （x2=7.977,P=0.005）,the survival rates in patients with MELD≥26.1 and with MELD<26.1 were 45.5% and 79.6%,and the survival rates in patients greater than 40-yr-old and under 40 were 50.8% and 79.5%,respectively （all P<0.05）. Conclusion Serum DAO levels might be used as a new parameter for predicting the prognosis of patients with ACLF,which needs further investigation.

Key words: Acute-on-chronic liver failure, Hepatitis B, Diamine oxidase, Prognosis

朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.

Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure[J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.

参考文献

[1] Görnbok H,Rödgaard-Hansen S,Aagaard NK,et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure(ACLF). J Hepatol,2016,4(4):813-822.
[2] 黄小平,吴云辉,王艳,等. 慢加急性肝衰竭前期患者血清M30和M65水平预测预后价值探讨. 实用肝脏病杂志,2016,19(3):301-304.
[3] 刘性涛. 慢加急性乙型肝炎肝衰竭患者血清内毒素和SIRS发生对多器官功能衰竭的影响. 实用肝脏病杂志,2017,20(6):758-759.
[4] Cai YJ,Dong JJ,Dong JZ,et. al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. Aliment Pharmacol Ther,2017,45(11):1413-1426.
[5] Alexopoulou A,Vasilieva L,Mani I,et al.Single center validation of mortality scores in patients with acute decompensation of cirrhosis with and without acute-on-chronic liver failure. Scand J Gastroenterol,2017,52(12):1385-1390.
[6] Sarin SK,Kedarisetty CK,Abbas Z,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int,2014,8(4):453-471.
[7] Barosa R,Roque RL,Patita M,et al.CLIF-C ACLF score is a better mortality predictor than MELD,MELD-Na and CTP in patients with acute on chronic liver failure admitted to the ward. Rev Esp Enferm Dig,2017,109(6):399-405.
[8] Lee YI,Smith RL,Gartshteyn Y,et al.Predictors of acute hemodynamic decompensation in early sepsis:An observational study. J Clin Med Res,2016,8(8):575-581.
[9] Katre RS,Sunnapwar A,Restrepo CS,et al.Cardiopulmonary and gastrointestinal manifestations of eosinophil-associated diseases and idiopathic hypereosinophilic syndromes:multimodality imaging approach. Radiographics,2016,36(2):433-451.
[10] Takeuchi T,Harada Y,Moriyama S,et al.Vesicular polyamine transporter mediates vesicular storage and release of polyamine from mast cells. J Biol Chem,2017,292(9):3909-3918.
[11] Arroyo V,Moreau R.Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis. J Hepatol,2017,66(2):451-453.
[12] Li HC,Fan XJ,Chen YF,et al.Early prediction of intestinal mucosal barrier function impairment by elevated serum procalcitonin in rats with severe acute pancreatitis. Pancreatology,2016,16(2):211-217.
[13] Liu L,Ji P,Qu N,et al.The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer. Oncol Lett,2016,12(1):504-512.
[14] Shah A,Shanahan E,Macdonald GA,et al.Systematic review and meta-analysis:prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis,2017,37(4):388-400.
[15] Kapil S,Duseja A,Sharma BK,et al.Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol,2016,31(1):213-221.
[16] Sarosiek I,Bashashati M,Alvarez A,et al.Lubiprostone accelerates intestinal transit and alleviates small intestinal bacterial overgrowth in patients with chronic vonstipation. Am J Med Sci,2016,352(3):231-238.
[17] Karhu E,Forsgörd RA,Alanko L,et al. Exercise and gastrointestinal symptoms: running-induced changes in intestinal permeability and markers of gastrointestinal function in asymptomatic and symptomatic runners. Eur J Appl Physiol,2017,117(12):2519-2526.
[18] Topal NB,Sarkut P,Dündar HZ,et al.The correlation between Doppler US measurement of hepatic arterial flow and the MELD score in patients with chronic liver disease. Eur Rev Med Pharmacol Sci,2016,20(2):291-296.
[19] Lei Q,Zhang Y,Ke C,et al.Value of the albumin-bilirubin score in the evaluation of hepatitis B virus-related acute-on-chronic liver failure,liver cirrhosis,and hepatocellular carcinoma. Exp Ther Med,2018,15(3):3074-3079.
[20] Cai F,Li AC,Li YK,et al.Plasma concentration of diamine oxidase (DAO) predicts 1-month mortality of acute-on-chronic hepatitis B liver failure. Clinica Chimica Acta,2018,484:164-170.

慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*

Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[7]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[8]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[9]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[10]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[11]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[12]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[13]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[14]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[15]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.